Medytox Decides on a 130.7 Billion KRW Paid-in Capital Increase

[Asia Economy Reporter Kim Heung-soon] Medytox announced on the 27th that it has decided to conduct a paid-in capital increase through a rights offering followed by a general public offering of forfeited shares worth 130.7 billion KRW to raise funds for facilities, operations, and debt repayment. The new shares consist of 971,763 common shares, with a scheduled issue price of 134,500 KRW per share. Existing shareholders can apply for subscription of the new shares from October 14 to 15. General investors can subscribe from October 19 to 20, with the payment date on the 22nd. Of the raised funds, 71.9 billion KRW will be used for operating expenses, 38 billion KRW will be used to repay existing debt, and 20.8 billion KRW will be allocated for facility funds. Medytox also plans to conduct a bonus issue concurrently. Based on October 23, the day after the payment for the paid-in capital increase, 0.2 new shares will be allocated per share.

This content was produced with the assistance of AI translation services.